Viatris (VTRS) Change in Receivables (2020 - 2026)
Viatris (VTRS) posted quarterly Change in Receivables of $126.3 million for Q1 2026, up 175.18% year-over-year from $45.9 million in Q1 2025, and up 146.45% quarter-over-quarter from -$271.9 million in Q4 2025.
Viatris (VTRS) Change in Receivables (2020 - 2026) Analysis & Trends
Viatris' Change in Receivables history runs 7 years deep, the most recent figure standing at $126.3 million for Q1 2026.
- In Q1 2026, Change in Receivables rose 175.18% year-over-year to $126.3 million; the TTM figure through Mar 2026 stood at -$40.3 million (up 91.21% YoY), while the FY2025 annual figure was -$334.6 million, down 11.5% from the prior year.
- Change in Receivables for Q1 2026 stood at $126.3 million, up from -$271.9 million in the prior quarter.
- The five-year high for Change in Receivables was $339.2 million in Q4 2022, with the low at -$300.5 million in Q4 2024.
- The 5-year median for Change in Receivables is $9.6 million (2025), against an average of -$20.4 million.
- The sharpest annual moves came in 2022 and 2025: Change in Receivables jumped 3361.22% in 2022, then plunged 1614.29% in 2025.
- Viatris' Change in Receivables stood at $339.2 million in 2022, then tumbled by 124.0% to -$81.4 million in 2023, then sank by 269.16% to -$300.5 million in 2024, then grew by 9.52% to -$271.9 million in 2025, then jumped by 146.45% to $126.3 million in 2026.
- Business Quant data shows VTRS's Change in Receivables at $126.3 million in Q1 2026, -$271.9 million in Q4 2025, and $95.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn | 48.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 126.50 Mn |
| Jun 30, 2026 | 126.50 Mn |
| Mar 31, 2026 | 126.30 Mn |
| Mar 31, 2026 | 126.30 Mn |
| Dec 31, 2025 | -271.90 Mn |
| Dec 31, 2025 | -271.90 Mn |
| Sep 30, 2025 | 95.70 Mn |
| Sep 30, 2025 | 95.70 Mn |
| Jun 30, 2025 | 9.60 Mn |
| Jun 30, 2025 | 9.60 Mn |
| Mar 31, 2025 | -168.00 Mn |
| Mar 31, 2025 | -168.00 Mn |
| Dec 31, 2024 | -300.50 Mn |
| Dec 31, 2024 | -300.50 Mn |
| Sep 30, 2024 | 33.00 Mn |
| Sep 30, 2024 | 33.00 Mn |
| Jun 30, 2024 | -22.80 Mn |
| Jun 30, 2024 | -22.80 Mn |
| Mar 31, 2024 | -9.80 Mn |
| Mar 31, 2024 | -9.80 Mn |